-
Product Insights
New![]()
Net Present Value Model: Chinook Therapeutics Inc’s Zigakibart
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
![]()
Pulse Oximeter Systems Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Pulse Oximeter Systems Pipeline Market Report Overview The Pulse Oximeter System is a photoelectric instrument for measuring the oxygen saturation of blood. The Pulse Oximeter Systems pipeline market research report provides comprehensive information about the Pulse Oximeter Systems pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that are in progress. Key Segments ·      Pulse Oximeter Sensors ·      Wrist Pulse Oximeters ·      Finger Pulse Oximeters ·      Handheld Pulse Oximeters...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: PRS-342 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Hepatocellular Carcinoma Drug Details: PRS-342 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Solid Tumor Drug Details: PRS-342 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bersiporocin in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Bersiporocin in Idiopathic Pulmonary Fibrosis Drug Details:Bersiporocin (DWN-12088, DWJ-209) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOAd-703 in Metastatic Biliary Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LOAd-703 in Metastatic Biliary Tract Cancer Drug Details: LOAd-703 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GSK-2636771 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GSK-2636771 in Refractory Multiple MyelomaDrug Details:GSK-2636771 is under development for the treatment of advanced refractory lymphoma...
-
Product Insights
New![]()
Net Present Value Model: Shanghai Junshi Biomedical Technology Co Ltd’s Ongericimab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Shanghai Junshi Biomedical Technology Co Ltd's Ongericimab Drug Details: Ongericimab (JS-002)Â is under development for the treatment of homozygous familial hypercholesterolemia, heterozygous non-familial and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine To Target Brachyury For Oncology in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine To Target Brachyury For Oncology in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: MVA-BN brachyury...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine To Target Brachyury For Oncology in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine to Target Brachyury for Oncology in Solid Tumor Drug Details: MVA-BN brachyury is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine To Target Brachyury For Oncology in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine To Target Brachyury For Oncology in Breast Cancer Drug Details: MVA-BN brachyury is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Ovarian Cancer Drug Details: Zilovertamab vedotin is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Pancreatic Cancer Drug Details: Zilovertamab vedotin is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Ureter Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Ureter Cancer Drug Details: Zilovertamab vedotin is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Solid Tumor Drug Details: Zilovertamab vedotin is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Lymphoma Drug Details: Zilovertamab vedotin is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Diffuse Large B-Cell Lymphoma Drug Details: Zilovertamab vedotin is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Bladder Cancer Drug Details: Zilovertamab vedotin is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.